Differences in treatment response to a total diet replacement intervention versus a food-based intervention: A secondary analysis of the OPTIWIN trial.
behavioural weight loss
total diet replacement
treatment response
Journal
Obesity science & practice
ISSN: 2055-2238
Titre abrégé: Obes Sci Pract
Pays: United States
ID NLM: 101675151
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
26
04
2020
revised:
30
06
2020
accepted:
25
07
2020
entrez:
23
12
2020
pubmed:
24
12
2020
medline:
24
12
2020
Statut:
epublish
Résumé
For every weight loss treatment, there are usually groups of people who lose less than expected. This study sought to determine if response rates to a total diet replacement (TDR) differed from those of a calorie-restricted, food-based (FB) diet. Data from OPTIWIN, a 12-month multicenter trial in adults with a BMI of 30-55 kg/m There were 103 (76%) responders in the OP compared with 78 (57%) in the FB group at 12 months. The odds of treatment response at 12 months among participants who were non-responders at 3 months was not significantly different between the OP and FB groups ( Early treatment response is more likely and better sustained with TDR compared with an FB diet. Individual and treatment level factors appear to influence early treatment response to behavioural interventions for weight reduction.
Identifiants
pubmed: 33354339
doi: 10.1002/osp4.444
pii: OSP4444
pmc: PMC7746973
doi:
Types de publication
Journal Article
Langues
eng
Pagination
605-614Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK020572
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK089503
Pays : United States
Informations de copyright
© 2020 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
JDA and JL are consultants for Nestlé Healthcare Nutrition; JDA, KHL, AER and LM receive grant funding from Nestlé Health Science; and SP is an employee of Nestlé Health Science. All remaining authors have no relevant disclosures. Nestlé Healthcare Nutrition owns the OPTIFAST programme.
Références
J Psychosom Res. 1985;29(1):71-83
pubmed: 3981480
Appetite. 2018 Jan 1;120:431-441
pubmed: 28958900
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
Obesity (Silver Spring). 2019 Jan;27(1):22-29
pubmed: 30421863
Curr Diab Rep. 2017 Sep;17(9):69
pubmed: 28726155
Int J Behav Med. 2015 Aug;22(4):471-80
pubmed: 25331853
Obesity (Silver Spring). 2014 Jul;22(7):1608-16
pubmed: 24771618
Psychol Med. 1982 Nov;12(4):871-8
pubmed: 6961471
Am Psychol. 2020 Feb-Mar;75(2):235-251
pubmed: 32052997
Circulation. 2005 Oct 25;112(17):2735-52
pubmed: 16157765
BMC Obes. 2015 Mar 01;2:11
pubmed: 26217526
Obesity (Silver Spring). 2019 Apr;27(4):591-602
pubmed: 30900410
Lancet Diabetes Endocrinol. 2019 May;7(5):344-355
pubmed: 30852132
Curr Obes Rep. 2016 Jun;5(2):282-90
pubmed: 27023070
Diabetes Care. 2002 Dec;25(12):2165-71
pubmed: 12453955
JAMA. 2012 Jun 27;307(24):2617-26
pubmed: 22735431
Diabetes Obes Metab. 2016 Jun;18(6):558-70
pubmed: 26936802
BMJ. 2015 Feb 05;350:g7846
pubmed: 25656059
Obesity (Silver Spring). 2011 Aug;19(8):1609-15
pubmed: 21455122